TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02833181

Intervention type: DEVICE
Intervention: BIS monitor
Description: Monitoring circadian variation of EEG

Intervention type: DEVICE
Intervention: BIS monitor
Description: Monitoring circadian variation of EEG

Intervention type: DEVICE
Intervention: BIS monitor
Description: Monitoring circadian variation of EEG
Study: NCT06502301

Intervention type: OTHER
Intervention: Cross-sectional study
Description: This is not intervention study.

Intervention type: OTHER
Intervention: Cross-sectional study
Description: This is not intervention study.
Study: NCT02826694

Intervention type: GENETIC
Group type: OTHER
Intervention: Well infant, whole exome sequencing
Description: Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.

Intervention type: GENETIC
Group type: OTHER
Intervention: Diagnosed, whole exome sequencing
Description: In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
Study: NCT04419350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
Study: NCT01559285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% ropivacaine concentration
Description: 0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.375% ropivacaine concentration
Description: 0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine concentration
Description: 0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
Study: NCT03722030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength-Training
Description: 2 sessions per week (20-40 min), home-based resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-point Measures
Description: Accelerometer (steps)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mid-point Measures
Description: Accelerometer (steps)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Study Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post-Study Measures
Description: Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
Study: NCT03134638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Part 1)
Description: Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
Study: NCT00367471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: An alkylating agent used in the treatment of some cancers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: An alkylating agent used in the treatment of some cancers
Study: NCT03134638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Cohort 2)
Description: In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Cohort 5)
Description: In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Part 2 Single Agent)
Description: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Part 2 Single Agent)
Description: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
Study: NCT00367471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: A monoclonal antibody that interferes with the HER2/neu receptor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: A mitotic inhibitor used in cancer treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: A mitotic inhibitor used in cancer treatment
Study: NCT00715715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Priming
Description: For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
Study: NCT01674426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: 16 sessions of 45 minutes each to review stress management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavior therapy
Description: 16 sessions of 45 minutes each to review stress management
Study: NCT01736683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
Study: NCT02817438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Days Ahead
Description: Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
Study: NCT00827203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elesclomol Sodium
Description: Chemotherapy agent
Study: NCT04923373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard physiotherapy
Description: standard physiotherapy
Study: NCT04265534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat
Description: Oral Glutaminase Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin Chemotherapy
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Chemotherapy
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed Chemotherapy
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Chemotherapy
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab Immunotherapy
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Immunotherapy
Description: IV infusion
Study: NCT03134638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-1365 (Part 2 Single Agent)
Description: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
Study: NCT04265534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid 400 -1000 μg
Description: Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 400 -1000 μg
Description: Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study: NCT04369339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colposcopy
Study: NCT04055935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elevation of full thickness mucoperiosteal flap
Description: A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
Study: NCT00003766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Study: NCT02189226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)
Description: Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)
Description: Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
Study: NCT04118335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Mulberry Syrup
Description: The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
Study: NCT00374231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
Study: NCT01002963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 30 mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 100 mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 300 mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 1000 mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 3000 mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 4500 mg, single

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04418948
Description: solution, 6000 mg, single
Study: NCT00540995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT00736476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H.pylori vaccines
Description: 1 dose of H.pylori vaccine at 0, 1, and 2 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo Vaccine at 0, 1, and 2 months
Study: NCT01261377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-level positive airway pressure (BPAP)
Description: The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
Study: NCT00552500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote (valproate)
Description: 500 mg -2000 mg QD based on individual tolerance and VPA levels
Study: NCT04055935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
Study: NCT02409498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pudendal block
Description: preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
Study: NCT00540995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Stem cell transplantation occurs on Day 0 after High Dose Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Stem cell transplantation occurs on Day 0 after High Dose Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Stem cell transplantation occurs on Day 0 after High Dose Therapy
Study: NCT02409498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no pudendal block
Description: preemptive pudendal nerve blockade with 10 ml of normal saline to each side
Study: NCT04354051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
Study: NCT02412007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized comprehensive home centred activity based programme
Description: Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized comprehensive home centred activity based programme
Description: Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing
Study: NCT02383394

Intervention type: OTHER
Intervention: follow up antenatal care
Description: ultrasound follow up of pregnancy
Study: NCT03905434

Intervention type: GENETIC
Intervention: miRNA sampling
Description: Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)

Intervention type: GENETIC
Intervention: miRNA sampling
Description: Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)